

## **ATTACHMENT 1**

### ***Curriculum Vitae* of Dr. Stephen Pakola**

## **Stephen J. Pakola, M.D.**

11 Meadow Way  
Irvington, NY 10533  
Home Phone: 1-914-674-1947  
email: [steve.pakola@thrombogenics.com](mailto:steve.pakola@thrombogenics.com)

**Professional Summary:** A licensed physician with over 13 years of clinical trial experience, including over 11 years of full-time Pharma/Biotech experience in roles of increasing responsibility (currently Chief Medical Officer of ThromboGenics and member of the Board of Directors of ThromboGenics Ltd.).

### **Education**

M.D., University of Pennsylvania, Philadelphia, PA, 1994

- \*Alpha Omega Alpha (national medical honor society) elected 1993
- \*Charles A. Oliver Prize (awarded annually to a graduating medical student at the University of Pennsylvania), 1994

B.A., University of Pennsylvania, Philadelphia, PA, 1990

- \*Summa cum laude (GPA-3.9) with honors in biology
- \*Phi Beta Kappa, elected 1989

### **Professional Experience**

- |              |   |
|--------------|---|
| 5/00-Present | Chief Medical Officer (Promoted from Senior VP in 6/06, promoted from VP on 7/02)<br>Member of the Board of Directors, ThromboGenics Ltd.<br>*Responsible for the company's worldwide clinical development programs (vitreoretinal disease, AMI, ischemic stroke, DVT prophylaxis, oncology, and other programs to enter clinical development in future)<br>*Program Leader for microplasmin-vitreoretinal program.   |
| 11/98-5/00   | Associate Director, Cardiovascular Clinical Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT<br><br>*U.S. clinical leader for oral direct thrombin inhibitor (BIBR) program<br>*Global Medical Leader of clinical development program for BIBB 1464, a lipid-lowering agent.<br>*Named to Clinical Expert Committee for risk factor intervention (internal expert group to review discovery/development plans for Boehringer Ingelheim worldwide) |
| 6/97-11/98   | Associate Director, Organon, Inc. CNS Clinical, West Orange, NJ   |

- \*Clinical Development Team Leader for gepirone (prior to departure, in charge of the preparation of the clinical section of NDA and clinical development plan for US)
- \*Unit head award recipient, 1<sup>st</sup> quarter, 1998 (awarded by executive director of clinical department to employees who have made significant contributions to the department)
- \*Study manager for 2 multicenter clinical trials (phase III ten-site trial and a phase IV, five-site trial)
- \*Responsible for safety related issues for U.S. phase II-IV trials on all CNS projects.

1996-1997      Senior Medical Scientist, Cardiovascular Division, Quintiles, Inc., Research Triangle Park, N.C.

- \*Project Medical Officer on all clinical trials in the U.S. Cardiovascular division, including phase I through global phase III trials (including GUARDIAN trial)
- \*Presented at FDA Advisory Committee meeting, as well as numerous investigator meetings

1995-1996      Research Scientist and Ophthalmology Resident, University of Pennsylvania, F.M. Kirby Center for Gene Therapy

- \*Planned and performed experiments in biotechnology arena, including virus vector gene transfer techniques
- \*Authored multiple publications (including one book chapter), and presented work at 4 national meetings
- \*Served as a reviewer for a medical journal

1994-1995      Medical Intern Physician, Presbyterian Medical Center (Affiliate of University of Pennsylvania Medical Center), Philadelphia, PA

#### **Other**

- \*99% on GMAT (Graduate Management Admission Test)
- \*Unrestricted license to practice medicine (License: NC 9700351)
- \*Married with 3 children

## Original Papers

Pakola SJ and Grunwald JE: Effects of oxygen and carbon dioxide on human retinal circulation. *Investigative Ophthalmology & Visual Science* 34(10): 2866-70, 1993.

MacGregor RR, Pakola SJ, Graziani AL, et al: CMV infection in clinically stable HIV-infected individuals with CD4-positive lymphocyte counts below 100/ul of blood: prevalence and relationship to risk of subsequent CMV retinitis. *Journal of AIDS* 10:324-30, 1995.

Pakola SJ, Dinges DF, Pack AI: Review of regulations and guidelines for commercial and non-commercial drivers with sleep apnea and narcolepsy. *Sleep* 18 (9): 787-96, 1995.

Pakola SJ, Nichols CW: CD8+ cells and cytomegalovirus retinitis in AIDS patients (correspondence). *Am. J. Ophthalmol.* 121(4): 455, 1996

Bennett J, Pakola S, Zenk Y, Maguire A: Humoral response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space. *Human Gene Therapy* 7(14): 1763-9, 1996

Balcer L, Galetta S, Bagley L, Pakola S: Localization of traumatic oculomotor nerve palsy to the midbrain exit sight by M.R.I. *Am. J. Ophthalmol.* 122(3): 437-9, 1996.

Lapchak PA, Araujo DM, Pakola SJ, Song D, Wei J, Zivin JA.: Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. *Stroke.* 33: 2279-2284, 2002.

Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera M, Bode C, Adgey AA, Bar F, Vahanian A, Van de Werf F; CAPTORS II Investigators. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). *Am Heart J.* 146(3):484-8, 2003.

Rasmussen RS, Overgaard K, Pakola S, Boysen G. Microplasmin may improve recovery in a rat embolic stroke model. *Neurol Res.* 2007 Jun 19; [Epub ahead of print].

Sakuma T, Tanaka M, Mizota A, Junji Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. *Invest Ophthalmol Vis Sci.* 2005 Sep;46(9):3295-9.

## Chapters

Pack AI, Pakola SJ, Findley LJ: Regulations for driving for patients with sleep disorders. *Forensic aspects of sleep.* Edited by Shapiro C, McCall-Smith. A. John Wiley & Sons Limited, 1996.